Hannah Clarke

Patient-reported outcomes from the EV-302 trial found consistent efficacy and safety outcomes for patients with urothelial carcinoma.

Neoadjuvant avelumab plus cisplatin yielded high event-free survival in muscle-invasive urothelial carcinoma.

Findings from a retrospective analysis indicate that treatment in non-academic cancer centers correlates with a decreased rate of immunotherapy use among patients with advanced clear cell renal cell carcinoma.

Data from the MAGNITUDE trial support the positive benefit/risk profile of niraparib plus abiraterone acetate and prednisone as a treatment for those with BRCA-mutated metastatic castration-resistant prostate cancer.

Findings from the ENZA-p study provide evidence for enhanced anti-cancer effects with 177Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Findings from the phase 3 SWOG S1011 trial highlight no significant differences between extended lymphadenectomy vs standard lymphadenectomy in terms of disease-free survival in patients with muscle-invasive breast cancer.

A recent phase 3 trial of the combination included a total of 398 patients with metastatic castration-resistant prostate cancer, unselected for homologous recombination repair gene alterations, in the safety cohort.

Findings from an interim analysis of data show that the addition of blue light cystoscopy to conventional white light significantly improved clinical outcomes in a group of patients with non–muscle-invasive bladder cancer.